253 related articles for article (PubMed ID: 20010156)
41. CRP: star trekking the galaxy of risk markers.
Després JP
Lancet; 2011 Feb; 377(9764):441-2. PubMed ID: 21277015
[No Abstract] [Full Text] [Related]
42. The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant?
van der Sande FM; Kooman JP; Leunissen KM
Blood Purif; 2006; 24(4):335-41. PubMed ID: 16557022
[TBL] [Abstract][Full Text] [Related]
43. Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management.
Gupta M; Singh N; Tsigoulis M; Kajil M; Hirjikaka S; Quan A; Teoh H; Verma S
Can J Cardiol; 2012; 28(1):14-9. PubMed ID: 22264843
[TBL] [Abstract][Full Text] [Related]
44. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
[No Abstract] [Full Text] [Related]
45. Role of C-reactive protein in cardiovascular disease.
Backes JM; Howard PA; Moriarty PM
Ann Pharmacother; 2004 Jan; 38(1):110-8. PubMed ID: 14742804
[TBL] [Abstract][Full Text] [Related]
46. C-reactive protein levels and outcomes after statin therapy.
Greenland P; Lloyd-Jones DM; Moss AJ
N Engl J Med; 2005 Apr; 352(15):1603-5; author reply 1603-5. PubMed ID: 15832450
[No Abstract] [Full Text] [Related]
47. [Less vascular risk with rosuvastatin in elevated CRP].
Bredie B
Ned Tijdschr Geneeskd; 2009 Feb; 153(6):245. PubMed ID: 19271446
[No Abstract] [Full Text] [Related]
48. [C-reactive protein potential risk factor for cardiovascular disease].
Tornvall P; Pernow J; Hansson LO
Lakartidningen; 2003 Aug; 100(35):2691-3. PubMed ID: 14531129
[TBL] [Abstract][Full Text] [Related]
49. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
Jeppesen J; Hansen TW; Olsen MH; Rasmussen S; Ibsen H; Torp-Pedersen C; Hildebrandt PR; Madsbad S
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):594-8. PubMed ID: 18753952
[TBL] [Abstract][Full Text] [Related]
50. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure.
Skoglund PH; Arpegård J; Ostergren J; Svensson P
Am J Hypertens; 2014 Mar; 27(3):363-71. PubMed ID: 24470529
[TBL] [Abstract][Full Text] [Related]
51. An overview of inflammatory markers in type 2 diabetes from the perspective of the clinical chemist.
Kimberly MM; Cooper GR; Myers GL
Diabetes Technol Ther; 2006 Feb; 8(1):37-44. PubMed ID: 16472049
[TBL] [Abstract][Full Text] [Related]
52. Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk.
Nambi V; Ballantyne CM
Curr Atheroscler Rep; 2005 Feb; 7(1):22-8. PubMed ID: 15683598
[TBL] [Abstract][Full Text] [Related]
53. [Does JUPITER change the daily routine of our practice?].
Schlossberg D
Praxis (Bern 1994); 2009 Mar; 98(6):302. PubMed ID: 19291635
[No Abstract] [Full Text] [Related]
54. New frontiers for cardiac risk assessment: C-reactive protein.
Martin CM; Almond J
Consult Pharm; 2006 Mar; 21(3):188-91, 195-6, 205-6. PubMed ID: 16573367
[TBL] [Abstract][Full Text] [Related]
55. Inflammatory bio-markers and cardiovascular risk prediction.
Blake GJ; Ridker PM
J Intern Med; 2002 Oct; 252(4):283-94. PubMed ID: 12366601
[TBL] [Abstract][Full Text] [Related]
56. [Questionable CRP and statin study].
Røiri P
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1238. PubMed ID: 19533830
[No Abstract] [Full Text] [Related]
57. By the way, doctor. I read about statin having anti-inflammatory effects and lowering CRP levels. So why are we now being told that some people need to take two anti-inflammatories--aspirin and a statin?
Lee TH
Harv Health Lett; 2009 Feb; 34(4):8. PubMed ID: 19260154
[No Abstract] [Full Text] [Related]
58. [Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events].
Schwarzer R; Schnell-Inderst P; Grabein K; Göhler A; Stollenwerk B; Grandi N; Klauss V; Wasem J; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2009; 103(6):319-29. PubMed ID: 19839204
[TBL] [Abstract][Full Text] [Related]
59. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice.
Avan A; Tavakoly Sany SB; Ghayour-Mobarhan M; Rahimi HR; Tajfard M; Ferns G
J Cell Physiol; 2018 Nov; 233(11):8508-8525. PubMed ID: 29932219
[TBL] [Abstract][Full Text] [Related]
60. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions.
de Ferranti S; Rifai N
Clin Chim Acta; 2002 Mar; 317(1-2):1-15. PubMed ID: 11814453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
